Equities Analysts Offer Predictions for ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Wedbush boosted their FY2024 earnings estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($2.25) per share for the year, up from their previous estimate of ($2.33). Wedbush has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.63) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

Several other brokerages have also recently commented on ZNTL. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. Guggenheim decreased their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, HC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Up 4.8 %

Shares of NASDAQ ZNTL opened at $1.74 on Monday. The stock’s fifty day simple moving average is $2.94 and its 200 day simple moving average is $3.26. The stock has a market capitalization of $123.99 million, a price-to-earnings ratio of -0.70 and a beta of 1.86. Zentalis Pharmaceuticals has a 52-week low of $1.66 and a 52-week high of $18.07.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. American Century Companies Inc. bought a new stake in Zentalis Pharmaceuticals during the second quarter worth approximately $95,000. Bank of Montreal Can bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth $402,000. Squarepoint Ops LLC grew its stake in Zentalis Pharmaceuticals by 543.8% in the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock valued at $608,000 after buying an additional 125,649 shares during the last quarter. Algert Global LLC bought a new position in Zentalis Pharmaceuticals in the 2nd quarter worth $78,000. Finally, SG Americas Securities LLC lifted its position in Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock worth $96,000 after acquiring an additional 11,997 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.